Compounded semaglutide and Wegovy share the same active ingredient and mechanism — the real differences are regulatory status, manufacturing source, and price.
Luma Health's compounded semaglutide is $197/month, flat, prepared by a licensed 503A pharmacy, versus Wegovy's retail list price of roughly $1,100-$1,350/month.
When patients learn that compounded semaglutide costs a fraction of Wegovy's price, the first question is almost always whether it's really the same medication. The honest answer: fundamentally yes on the active ingredient, with real and important differences in how each is manufactured, regulated, and priced.
Same Active Ingredient, Different Manufacturing Path
Both compounded semaglutide and Wegovy contain semaglutide as the active molecule, working through the identical mechanism — GLP-1 receptor activation that reduces appetite, slows gastric emptying, and improves insulin sensitivity. Because the active ingredient is the same, the STEP clinical trial results (an average 14.9% body-weight reduction over 68 weeks at the 2.4mg maintenance dose) are directly relevant to what compounded semaglutide can achieve when patients follow the same dose-titration protocol.
Wegovy is manufactured by Novo Nordisk as a finished, FDA-approved drug product in large-scale facilities under Good Manufacturing Practice standards, then reviewed and approved by the FDA as a specific product. Compounded semaglutide is prepared by a licensed compounding pharmacy per individual prescription, using pharmaceutical-grade semaglutide from FDA-registered facilities — a fundamentally different manufacturing and regulatory pathway, even though the underlying molecule is the same.
The Legal Basis for Compounding
Compounded semaglutide is legally produced under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, which allow licensed pharmacies to prepare medications, including patient-specific compounded versions of FDA-approved drugs, under defined conditions. This is distinct from the drug-shortage exception that also applied for a period when semaglutide was on the FDA's shortage list; 503A patient-specific compounding operates on its own legal basis rather than depending solely on shortage status. The regulatory landscape around bulk (503B) compounding of GLP-1 medications specifically has continued to evolve, which is part of why sourcing from a compounding pharmacy that's transparent about its licensing and process matters more than ever.
Look for a pharmacy that's licensed in your state and properly registered (503A or 503B), ideally with PCAB accreditation or equivalent, USP <797> sterile-compounding compliance, and a willingness to provide a certificate of analysis on request. Luma Health's compounded semaglutide is prepared by VialsRx, licensed by the Texas State Board of Pharmacy (license #35264), verifiable at pharmacy.texas.gov.
Cost Comparison
Wegovy's retail list price without insurance commonly runs $1,100-$1,350/month. Compounded semaglutide through licensed telehealth typically runs considerably lower — Luma Health's is $197/month, flat, regardless of dose. That price difference reflects the absence of large-scale manufacturing, marketing, and brand-drug development costs baked into Wegovy's pricing, not a difference in the core active ingredient.
Dosing and Titration
Compounded semaglutide generally follows the same dose-titration schedule as Wegovy — starting around 0.25mg weekly and increasing gradually over several weeks to a maintenance dose (commonly 1.7mg or 2.4mg weekly) based on response and tolerance. This gradual approach exists to minimize gastrointestinal side effects regardless of which version you're taking.
Which Path Fits You
- Have insurance that covers Wegovy specifically at an affordable copay
- Want the exact FDA-approved finished product
- Qualify for the manufacturer's savings card program
- Don't have insurance coverage for weight-loss GLP-1s
- Want flat, predictable pricing regardless of dose
- Are comfortable with a compounded (not brand-finished) product from a verifiably licensed pharmacy
Same active ingredient,
a fraction of the price
Compounded semaglutide at $197/month, flat — prepared by a licensed, verifiable 503A pharmacy, with a real medical evaluation included.
Get Started → Or start your free health assessmentFrequently Asked Questions
Since both contain the same active ingredient at equivalent doses, the underlying pharmacological effect is the same. Effectiveness in practice depends on following the same dose-titration protocol and on the compounding pharmacy's quality standards.
No. Compounded semaglutide is not itself an FDA-approved finished drug product, though its active ingredient is FDA-approved in commercial formulations like Wegovy and Ozempic. It's legally produced under Sections 503A and 503B of the FD&C Act by licensed compounding pharmacies.
Compounding pharmacies don't carry the same large-scale manufacturing, marketing, and brand-development costs as a pharmaceutical manufacturer, which is reflected in the price difference — not a difference in the core active ingredient.
Check the pharmacy's state board license directly, look for PCAB accreditation or USP <797> sterile-compounding compliance, and ask whether a certificate of analysis is available. Luma Health's pharmacy partner is verifiable at pharmacy.texas.gov.
Generally yes — starting at a low dose (around 0.25mg weekly) and titrating gradually to a maintenance dose based on response and tolerance, the same approach used with Wegovy.
Yes, with your provider's guidance. Since the active ingredient is the same, the transition is typically straightforward at an equivalent dose, without needing to restart titration from scratch.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PubMed 33567185
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. PubMed 35441470
- U.S. Food and Drug Administration. Prescribing Information for Wegovy (semaglutide). FDA.gov. 2025. FDA Drug Approvals Database
- U.S. Food and Drug Administration. Human Drug Compounding and the FD&C Act. FDA.gov. FDA.gov
- Texas State Board of Pharmacy. Pharmacy license lookup and verification. pharmacy.texas.gov